Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals develops and commercializes therapies for people with autoimmune diseases. Its marketed product is LUPKYNIS (voclosporin), an oral therapy used with background immunosuppressive treatment for adults with active lupus nephritis. Aurinia markets LUPKYNIS in the United States through its own commercial organization and sells it to specialty pharmacies and a specialty distributor. Otsuka markets the product in Japan, the European Union, the United Kingdom and Switzerland; Aurinia supplies Otsuka with inventory and receives royalties on sales in its territories. Aurinia is also developing aritinercept, a dual BAFF and APRIL inhibitor under study for potential treatment of autoimmune diseases. The company earns money from LUPKYNIS product sales, supply and service arrangements with Otsuka, and royalties on Otsuka-territory sales. Aurinia is headquartered in Edmonton, Alberta, Canada.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AUPH in the last 30 days.
See all $AUPH insider activity →RBC Capital kept its Sector Perform rating on Aurinia Pharmaceuticals but raised its price target to $18 from $16, suggesting an 8.1% upside from the Oct 30 close of $16.65.
Aurinia Pharmaceuticals reported Q3 and YTD 2026 results, with revenue up 14% and 19% respectively. Net product sales of LUPKYNIS increased 12% and 18%. Net income rose 21% and 67%. The company raised its 2026 revenue guidance and initiated new clinical studies for LUPKYNIS and aritinercept.
TD Cowen raised its price target for Aurinia Pharmaceuticals (AUPH) to $18 from $17, citing updated R&D cost estimates and durable growth of Lupkynis. The stock trades at $16.74, suggesting 7% upside. Aurinia also settled a patent dispute with Teva, extending voclosporin's exclusivity to 2036. Analysts expect continued revenue growth.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning AUPH (Aurinia Pharmaceuticals Inc.). Coverage has skewed bullish: 6 bullish, 1 neutral, and 2 bearish.
Recent AUPH coverage spans financial news, earnings and insider activity.
RBC Capital kept its Sector Perform rating on Aurinia Pharmaceuticals but raised its price target to $18 from $16, suggesting an 8.1% upside from the Oct 30 close of $16.65.
Guidance raise and strong revenue growth suggest upside pressure.
Analyst upgrade suggests upside potential.
Strong profit growth may support short-term upside, but higher R&D spend and cash burn could limit longer-term rally.
Minor dilution of insider ownership; unlikely to move price materially.
AlphAI scores every news story that mentions AUPH with an AI model for sentiment and relevance, and aggregates insider trades from Aurinia Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RBC Capital kept its Sector Perform rating on Aurinia Pharmaceuticals but raised its price target to $18 from $16, suggesting an 8.1% upside from the Oct 30 close of $16.65.
Aurinia Pharmaceuticals reported Q3 and YTD 2026 results, with revenue up 14% and 19% respectively. Net product sales of LUPKYNIS increased 12% and 18%. Net income rose 21% and 67%. The company raised its 2026 revenue guidance and initiated new clinical studies for LUPKYNIS and aritinercept.
TD Cowen raised its price target for Aurinia Pharmaceuticals (AUPH) to $18 from $17, citing updated R&D cost estimates and durable growth of Lupkynis. The stock trades at $16.74, suggesting 7% upside. Aurinia also settled a patent dispute with Teva, extending voclosporin's exclusivity to 2036. Analysts expect continued revenue growth.
Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.
Robertson Stephen P. (Chief Legal Officer) sold 11,939 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.95 ($0.19M total) on 2026-09-10.
Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.
Aurinia Pharmaceuticals (AUPH) officer Stephen P. Robertson plans to sell 47,000 shares under Rule 144 to cover tax obligations from vesting performance stock units, with the sale expected to occur on or after 08/21/2026. The transaction will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
Aurinia Pharmaceuticals (AUPH) settled with Teva, delaying generic competition for voclosporin until 2036. AUPH shares rose 13.77% in 7 days, 12.51% YTD, closing at $17.27. Revenue is projected to grow 16-21% this year, with EPS potentially doubling. The stock is considered 17.8% undervalued with a fair value of $21.00, but faces risks like concentration around Lupkynis.
Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.
Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.
